QUOTE AND NEWS
Benzinga  Oct 17  Comment 
Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga’s #PreMarket Prep to talk about why he...
GenEng News  Oct 15  Comment 
Protein remains at the top of methodologies for capturing or otherwise isolating monoclonal antibodies from bioprocess streams. Although resins have much higher capacities and lower sensitivity to cleaning agents than a decade ago, issues of cost,...
SeekingAlpha  Oct 10  Comment 
By InsiderInsights: Dollar value is only one metric to assess the significance of an insider transaction, but when high dollar value intersects with significance it spotlights a stock investors should take the time to consider. InsiderInsights...
SeekingAlpha  Oct 8  Comment 
By Trevor Lowenthal: A week ago, I wrote a bullish article on Ligand (NASDAQ:LGND), with a thesis stating that the company's outlook should improve with increasing royalty payments and new collaborations using its Captisol technology platform. I...
Benzinga  Oct 8  Comment 
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) ticked up Wednesday after the company said third-quarter results will be better than expected. The San Diego drug maker's shares are down nearly 30 percent in the past three months, but ticked up 2...
Benzinga  Oct 8  Comment 
GT Advanced Technologies (NASDAQ: GTAT) jumped 40.50% to $1.70 after surging 51.25% on Tuesday. Trio-Tech International (NYSE: TRT) climbed 9.45% to $3.59 on Q4 results. Blackhawk Network Holdings (NASDAQ: HAWK) shares surged 9.25% to $34.50...
SeekingAlpha  Sep 26  Comment 
By Trevor Lowenthal: In August, I wrote a bull article on Ligand (NASDAQ:LGND), with a thesis stating that the company's outlook should improve with increasing royalty payments and new collaborations through its Captisol technology platform. I...
SeekingAlpha  Sep 9  Comment 
By Trevor Lowenthal: In August, I wrote a bullish article on Ligand (NASDAQ:LGND), with a thesis stating that the company's outlook should improve with increasing royalty payments and new collaborations via its Captisol technology platform. I also...
StreetInsider.com  Aug 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ligand+Pharma+%28LGND%29+Reports+FDA+Approval+of+PromactaRevolade+sNDA/9786314.html for the full story.
SeekingAlpha  Aug 22  Comment 
By Amvona: Ligand Pharmaceuticals (NASDAQ:LGND): Institutional holders wasting no time dumping stock in response to mounting insolvency and bankruptcy risks Ligand's largest shareholder, BVF, Inc., sells 484,524 shares A PDF version of the...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki